Annovis Bio Inc
F:07X
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Annovis Bio Inc
F:07X
|
US |
|
M
|
Matsuda Sangyo Co Ltd
TSE:7456
|
JP |
|
Schaeffler India Ltd
NSE:SCHAEFFLER
|
IN |
|
S
|
Strathcona Resources Ltd
OTC:STHRF
|
CA |
|
Almarai Company SJSC
SAU:2280
|
SA |
Annovis Bio Inc
Annovis Bio is a clinical-stage drug developer focused on brain disorders tied to neurodegeneration, especially Alzheimer’s disease and Parkinson’s disease. It is trying to create medicines that protect nerve cells and improve memory, thinking, and movement by targeting the biological damage that builds up in these illnesses. The company does not sell approved medicines for patients yet. Its business is built around researching and testing drug candidates, then moving them through clinical trials and the regulatory process. If one of those candidates succeeds, Annovis would make money through product sales or a licensing deal with a larger drug company; for now, it mostly depends on outside financing to fund development. What makes Annovis different is its place in the value chain: it is a pure development-stage biotech, not a full pharmaceutical seller. Its customers are not consumers but rather the future healthcare system and, potentially, larger drugmakers that could partner on or commercialize its treatments if the science and trials work out.
Annovis Bio is a clinical-stage drug developer focused on brain disorders tied to neurodegeneration, especially Alzheimer’s disease and Parkinson’s disease. It is trying to create medicines that protect nerve cells and improve memory, thinking, and movement by targeting the biological damage that builds up in these illnesses.
The company does not sell approved medicines for patients yet. Its business is built around researching and testing drug candidates, then moving them through clinical trials and the regulatory process. If one of those candidates succeeds, Annovis would make money through product sales or a licensing deal with a larger drug company; for now, it mostly depends on outside financing to fund development.
What makes Annovis different is its place in the value chain: it is a pure development-stage biotech, not a full pharmaceutical seller. Its customers are not consumers but rather the future healthcare system and, potentially, larger drugmakers that could partner on or commercialize its treatments if the science and trials work out.
